Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients.
[BACKGROUND] Stage III non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase () gene rearrangements requires multimodal therapy.
- 95% CI 0.15-0.73
- HR 0.33
- 추적기간 48.9 months
- 연구 설계 cohort study
APA
Tan F, Jiang Y, et al. (2026). Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients.. Journal of the National Cancer Center, 6(2), 159-165. https://doi.org/10.1016/j.jncc.2025.07.005
MLA
Tan F, et al.. "Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients.." Journal of the National Cancer Center, vol. 6, no. 2, 2026, pp. 159-165.
PMID
42007220
Abstract
[BACKGROUND] Stage III non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase () gene rearrangements requires multimodal therapy. The ALINA trial demonstrated the efficacy of adjuvant tyrosine kinase inhibitors ( TKIs) in early-stage -positive NSCLC but provided limited long-term data for stage III patients. Real-world evidence is needed to validate and expand these findings.
[METHODS] This multicenter, real-world cohort study analyzed treatment patterns and clinical outcomes in 176 patients with stage III -positive NSCLC. The prognosis of different variants was evaluated. Inverse probability treatment weighting (IPTW) and sensitivity analyses were performed to adjust for the confounding factors.
[RESULTS] At a median follow-up of 48.9 months, the 5-year overall survival (OS) and progression-free survival (PFS) rates were 71.9 % and 14.8 %, respectively, with a median PFS of 19.5 months. Among all 176 patients, 144 (81.8 %) received definitive local therapy, including 132 who underwent surgery and 12 who received definitive chemoradiotherapy (CRT); the remaining 32 patients (18.2 %) received systemic therapy alone. The most common - variants were v1 (25.3 % of patients, = 23) and v3 (38.5 % of patients, = 35). v1 variants was associated with significantly better OS compared to other variants ( < 0.05). A total of 126 (71.6 %) patients relapsed, and 97 (55.1 %) had distant metastasis. Local treatment (HR = 0.33, 95 % CI: 0.15-0.73; = 0.007) and targeted therapy (HR = 0.34, 95 % CI: 0.17-0.69; = 0.003) were significant independent prognostic factors for better OS. Patients receiving local therapy and adjuvant TKIs achieved 100 % 5-year OS without progression. The sensitivity analysis yielded similar findings.
[CONCLUSIONS] This study provided long-term follow-up data that validated the findings of the ALINA trial. Stage III -positive NSCLC is prone to relapse but local therapy combined with adjuvant TKIs offers a promising strategy. Patients with v1 mutations may show improved outcomes.
[METHODS] This multicenter, real-world cohort study analyzed treatment patterns and clinical outcomes in 176 patients with stage III -positive NSCLC. The prognosis of different variants was evaluated. Inverse probability treatment weighting (IPTW) and sensitivity analyses were performed to adjust for the confounding factors.
[RESULTS] At a median follow-up of 48.9 months, the 5-year overall survival (OS) and progression-free survival (PFS) rates were 71.9 % and 14.8 %, respectively, with a median PFS of 19.5 months. Among all 176 patients, 144 (81.8 %) received definitive local therapy, including 132 who underwent surgery and 12 who received definitive chemoradiotherapy (CRT); the remaining 32 patients (18.2 %) received systemic therapy alone. The most common - variants were v1 (25.3 % of patients, = 23) and v3 (38.5 % of patients, = 35). v1 variants was associated with significantly better OS compared to other variants ( < 0.05). A total of 126 (71.6 %) patients relapsed, and 97 (55.1 %) had distant metastasis. Local treatment (HR = 0.33, 95 % CI: 0.15-0.73; = 0.007) and targeted therapy (HR = 0.34, 95 % CI: 0.17-0.69; = 0.003) were significant independent prognostic factors for better OS. Patients receiving local therapy and adjuvant TKIs achieved 100 % 5-year OS without progression. The sensitivity analysis yielded similar findings.
[CONCLUSIONS] This study provided long-term follow-up data that validated the findings of the ALINA trial. Stage III -positive NSCLC is prone to relapse but local therapy combined with adjuvant TKIs offers a promising strategy. Patients with v1 mutations may show improved outcomes.
같은 제1저자의 인용 많은 논문 (4)
- The Construction of a Multifunctional Nanoscale Porous Coordination Network-222 Nanodrug for Imaging-Guided Chemotherapy-Photodynamic Therapy.
- A Unified Framework for Survival Prediction: Combining Machine Learning Feature Selection with Traditional Survival Analysis in Heart Failure and METABRIC Breast Cancer.
- Multivalent aptamer engineered and functionalized NK cells for enhanced adoptive immunotherapy in CD30-positive malignant lymphoma.
- ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple Cancer Types.